Rheumatology, Stony Brook University Medical Center, New York, USA.
Osteoporos Int. 2010 Jun;21(6):1059-63. doi: 10.1007/s00198-009-1061-4. Epub 2009 Oct 27.
Fractures have a significant impact on the quality of life for the patient in addition to an enormous indirect cost in lost productivity for our economy. While majority of fractures heal uneventfully, some fail to heal even after many months resulting in nonunion.
Sternal nonunions, although rare, are particularly onerous for the patient given the magnitude of impact on quality of life.
Current treatment for fracture nonunions emphasizes various approaches to surgical fixation in addition to bone grafting. These treatments are aggressive and have a variety of drawbacks, rendering them suboptimal as a therapeutic approach.
Based on the success of teriparatide in animal studies to accelerate fracture healing, there is growing interest in using this drug in humans for the same purpose. We report a case of what we believe to be the first successful use of teriparatide in the healing of a sternal nonunion fracture.
骨折除了给我们的经济带来巨大的生产力损失这一间接成本外，还会对患者的生活质量产生重大影响。虽然大多数骨折都能顺利愈合，但有些骨折即使经过数月仍未能愈合，导致骨不连。
胸骨骨不连虽然罕见，但由于对生活质量的影响巨大，对患者来说尤其麻烦。
目前，骨折不愈合的治疗强调各种手术固定方法，并结合植骨。这些治疗方法具有侵袭性，且存在多种缺点，因此不是一种理想的治疗方法。
鉴于特立帕肽在动物研究中加速骨折愈合的成功，人们越来越有兴趣将该药用于人类的相同目的。我们报告了一例我们认为是特立帕肽首次成功用于胸骨骨不连骨折愈合的病例。
